RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta +19 more·2015·Nature Communications

DOI 10.1038/ncomms7377

Cited by (655)

Items 101–200 of 655

Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Eric E. Gardner, Ethan M. Earlie, Kate Li, Jerin Thomas, Melissa J. Hubisz, Benjamin D. Stein, Chen Zhang, Lewis C. Cantley, Ashley Marie Laughney, HAROLD E. VARMUS · 2024 · Science
RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis
Mu‐En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li et al. · 2023 · Journal of Clinical Investigation
Lineage Plasticity in Cancer Progression and Treatment
Clémentine Le Magnen, Michael M. Shen, Cory T. Abate-Shen · 2017 · Annual Review of Cancer Biology
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Valeria Smiroldo, M. Picciotto, Mariangela Zanghì, Christian Diego Rolfo, Vincenzo Adamo · 2017 · Critical Reviews in Oncology/Hematology
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia A. Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam et al. · 2023 · Cancer Cell
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2021 · Cancers
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Satyam Kumar Singh, Sushabhan Sadhukhan, Avinash Sonawane · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Differential impact of RB status on E2F1 reprogramming in human cancer
Christopher M. McNair, Kexin Xu, Amy C. Mandigo, Matteo Benelli, Benjamin E. Leiby, Daniel Nava Rodrigues, Johan Lindberg, Henrik Grönberg, Mateus Crespo, Bram De Laere et al. · 2017 · Journal of Clinical Investigation
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Agnieszka Katarzyna Witkiewicz, Sejin Chung, Rachel Brough, Paris J. Vail, Jorge Franco, Christopher J. Lord, Erik S. Knudsen · 2018 · Cell Reports
Hypoxia-driven intratumor heterogeneity and immune evasion
Stéphane Terry, Agnete S. T. Engelsen, Stéphanie Buart, Walid El‐Sayed, Goutham Hassan Venkatesh, Salem Chouaı̈b · 2020 · Cancer Letters
Cancer Plasticity: The Role of mRNA Translation
Laura J. Lee, David J. Papadopoli, Michael Jewer, Sonia Victoria Del Rincon, Ivan Topisirović, Mitchell G. Lawrence, Lynne-Marie M Postovit · 2020 · Trends in cancer
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, Dana S., Bivona, Trever G. · 2017 · npj Precision Oncology
Therapy considerations in neuroendocrine prostate cancer: what next?
Himisha Beltran, Francesca Demichelis · 2021 · Endocrine Related Cancer
Cellular and molecular biology of small cell lung cancer: an overview.
Niki Karachaliou, Sara Pilotto, Chiara Lazzari, Emilio Bria, Filippo de Marinis, Rafael Rosell · 2016 · Europe PMC (PubMed Central)
Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer
Tingting Wang, Xufang Chen, Weiwei Qiao, Lijun Kong, Daqing Sun, Zunling Li · 2017 · BMC Cancer
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer
Jiaye Lu, Jingwei Li, Ziyou Lin, Huaxuan Li, Linlin Lou, Wen Ding, Shumin Ouyang, Yonghui Wu, Yuanzhen Wen, Xiaobing Chen et al. · 2023 · Cancer Letters
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
Àlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian Ada Zhan, Maysun Hasan, Shweta S. Chavan, Fanli Meng, Fathema Z. Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai Shah et al. · 2021 · Journal of Hematology & Oncology
Drug Resistance to EGFR Inhibitors in Lung Cancer
Osamu Tetsu, Matthew J. Hangauer, Janyaporn Phuchareon, David W. Eisele, Frank P. McCormick · 2016 · Chemotherapy
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, Michael Möhr, Christoph Schliemann, Wolfgang E. Berdel, Lars Henning Schmidt · 2019 · Cancers
Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
Giuseppe Giaccone, Yongfeng He · 2023 · Seminars in Cancer Biology
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Matteo Canale, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Paola Ulivi · 2022 · Cancers
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
Kenichi Suda, Isao Murakami, Kazuko Sakai, Hiroshi Mizuuchi, Shigeki Shimizu, Katsuaki Sato, Kenji Tomizawa, Shuta Tomida, Yasushi Yatabe, Kazuto Nishio et al. · 2015 · Scientific Reports
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Mingrui Zhu, Yi Huang, Matthew E. Bender, Luc Girard, Rahul Krishna Kollipara, Buse Eglenen-Polat, Yujiro Naito, Trisha K. Savage, Kenneth E. Huffman, Shohei Koyama et al. · 2021 · Cancer Research
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
Naoki Takegawa, Hidetoshi Hayashi, Norishige Iizuka, Takayuki Takahama, H. Ueda, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa · 2016 · Annals of Oncology
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Tatiana Shaurova, Letian Zhang, David W. Goodrich, Pamela A. Hershberger · 2020 · Frontiers in Genetics
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
Matin Shaikh, Yashodeep Shinde, Rahul H. Pawara, Malleshappa N. Noolvi, Sanjay Javerilal Surana, Iqrar Ahmad, Harun Patel · 2021 · Journal of Medicinal Chemistry
Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features
Luan Nguyen, Arne van Hoeck, Edwin P. J. G. Cuppen · 2022 · Nature Communications
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
Dana W.Y. Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, Oscar M. Rueda, Christopher G. Smith, Dineika Chandrananda, Ross Andrew Soo, Hong Liang Lim, Boon Cher Goh, Carlos Caldas et al. · 2018 · EMBO Molecular Medicine
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Juan Bautista Blaquier, Sandra Ortiz‐Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, Gonzalo Recondo · 2023 · Clinical Cancer Research
The Dual Roles of the Atypical Protein Kinase Cs in Cancer
Miguel Reina‐Campos, Maria Teresa Díaz-Meco, Jorge Moscat · 2019 · Cancer Cell
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
Charu Aggarwal, Christiana W. Davis, Rosemarie Mick, Jeffrey C. Thompson, Saman Ahmed, Seth Jeffries, Stephen Joseph Bagley, Peter Edward Gabriel, Tracey L. Evans, Joshua Michael Bauml et al. · 2018 · JCO Precision Oncology
Clinical application of a lung cancer organoid (tumoroid) culture system
Etsuko Yokota, Miki Iwai, Takuro Yukawa, M. Yoshida, Yoshio Naomoto, Minoru Haisa, Yasumasa Monobe, Nagio Takigawa, Minzhe Guo, Yutaka Maeda et al. · 2021 · npj Precision Oncology
Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition
Wen Hwang, Yu-Fan Chiu, Ming-Han Kuo, Kuan-Lin Lee, An-Chun Lee, Chia-Cherng Yu, Junn-Liang Chang, Wen-Chien Huang, Shih-Hsin Hsiao, Sey‐En Lin et al. · 2017 · Cancer Research
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si‐Yang Liu, Hua Bao, Qun Wang, Weimin Mao, Yedan Chen, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yucheng Wei, Yong-Yu Liu et al. · 2021 · Nature Communications
Killing SCLC: insights into how to target a shapeshifting tumor
Kate D. Sutherland, Abbie S. Ireland, Trudy G. Oliver · 2022 · Genes & Development
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Joel Rivera‐Concepción, Dipesh Uprety, Alex A. Adjei · 2022 · Cancer Research and Treatment
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
Delphine Levacq, Nicky D’Haene, Roland de Wind, Myriam Remmelink, Thierry Berghmans · 2016 · Lung Cancer
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Cecilia López Sambrooks, Marta Baro, Amanda Quijano, Azeet Narayan, Wei Cui, Patricia Greninger, Regina K. Egan, Abhijit A. Patel, Cyril H. Benes, W. Mark Saltzman et al. · 2018 · Cancer Research
Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors
Rita Dorantes-Heredia, José Manuel Ruiz-Morales, Fernando Cano-García · 2016 · Translational Lung Cancer Research
A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
Liao, Sida, Davoli, Teresa, Leng, Yumei, Li, Mamie Z., Xu, Qikai, Elledge, Stephen J. · 2017 · Genes & Development
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Ahronian, Leanne G., Corcoran, Ryan B. · 2017 · Genome Medicine
Novel insights into RB1 mutation
Yiran Yao, Xiang Gu, Xiaofang Xu, Shengfang Ge, Renbing Jia · 2022 · Cancer Letters
Identifying a confused cell identity for esophageal squamous cell carcinoma
Xiangyu Pan, Jian Wang, Linjie Guo, Feifei Na, Jiajia Du, Xuelan Chen, Ailing Zhong, Lei Zhao, Lu Zhang, Mengsha Zhang et al. · 2022 · Signal Transduction and Targeted Therapy
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Li Zhang, Yalan Bi, Mengzhao Wang · 2019 · EBioMedicine
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance
Xiao-ming Jiang, Yu-Lian Xu, Luo-wei Yuan, Lele Zhang, Mu-yang Huang, Zi-han Ye, Min‐Xia Su, Xiu-ping Chen, Hong‐Jian Zhu, Richard D. Ye et al. · 2020 · Acta Pharmacologica Sinica
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
Mong‐Wei Lin, Kang‐Yi Su, Te-Jen Su, Chia‐Ching Chang, Jingwei Lin, Yi‐Hsuan Lee, Sung‐Liang Yu, Jin‐Shing Chen, Min‐Shu Hsieh · 2018 · Lung Cancer
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, G.M. Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno · 2024 · Critical Reviews in Oncology/Hematology
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53 -Mutated Prostate Cancer
Alexandra M. Blee, Yundong He, Yinhui Yang, Zhenqing Ye, Yuqian Yan, Yunqian Pan, Tao Ma, Joseph A. Dugdale, Emily Kuehn, Manish Kohli et al. · 2018 · Clinical Cancer Research
Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β 2 ‐AR/MACC1 axis
Changqie Pan, Jianhua Wu, Siting Zheng, Huiying Sun, Yisheng V. Fang, Zhenhua Huang, Min Shi, Liang Li, Jianping Bin, Yulin Liao et al. · 2021 · 癌症：英文版
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang · 2022 · Oncology Letters
Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists
Jumpei Kashima, Rui Kitadai, Yusuke Okuma · 2019 · Cancers
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Satoshi Yoda, Ibiayi Dagogo‐Jack, Aaron N. Hata · 2018 · Pharmacology & Therapeutics
Cyclin D degradation by E3 ligases in cancer progression and treatment
Shuo Qie, John Alan Diehl · 2020 · Seminars in Cancer Biology
Clinical characteristics and prognostic analysis of SMARCA4 ‐deficient non‐small cell lung cancer
Xiyue Liang, Xianzheng Gao, Feng Wang, Shenglei Li, Yashu Zhou, Peng Guo, Yuanyuan Meng, Taiying Lu · 2023 · Cancer Medicine
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu · 2018 · Critical Reviews in Oncology/Hematology
Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas
Ying Jin, Xun Shi, Jun Zhao, Qiong He, Ming Chen, Junrong Yan, Qiuxiang Ou, Xue Wu, Yang Washington Shao, Xinmin Yu · 2018 · Lung Cancer
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer
Franziska Böttger, Ekaterina A. Semenova, Ji‐Ying Song, Giustina Ferone, Jan van der Vliet, Miranda Cozijnsen, Rajith Bhaskaran, Lorenzo Bombardelli, Sander R. Piersma, Thang V. Pham et al. · 2019 · Cell Reports
Advances in Small-Cell Lung Cancer (SCLC) Translational Research
Benjamin Jacob Drapkin, Charles M. Rudin · 2020 · Cold Spring Harbor Perspectives in Medicine
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Meghan J. Campo, H. Al-Halabi, Melin Janardan Khandekar, Alice Tsang Shaw, Lecia Van Dam Sequist, Henning Willers · 2016 · The Oncologist
Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
Priyanka Bhateja, Michelle Chiu, Gary M. Wildey, Mary Beth Lipka, Pingfu Fu, Michael Yang, Fatemeh Ardeshir‐Larijani, Neelesh Sharma, Afshin Dowlati · 2019 · Cancer Medicine
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick H. Dinkelborg, Heike N. Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia Van Dam Sequist, Kerstin Borgmann et al. · 2019 · Cell Reports
Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
Yangyang Liu · 2018 · Cancer Biology & Therapy
Investigating Tumor Heterogeneity in Mouse Models
Tuomas Tammela, Julien Sage · 2019 · Annual Review of Cancer Biology
Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics
Peiye Shen, Ying Jing, Ruiyun Zhang, Mei‐Chun Cai, Pengfei Ma, Haige Chen, Guanglei Zhuang · 2018 · Oncogene
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
Stephanie P.L. Saw, Siqin Zhou, Jianbin Chen, Gillianne Geet Yi Lai, Mei‐Kim Ang, Kevin Lee Min Chua, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan et al. · 2021 · JAMA Network Open
FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma
Grace Orstad, Gabriela Fort, Timothy J. Parnell, Alex D. Jones, Chris Stubben, Brian K. Lohman, Katherine L. Gillis, Walter A. Orellana, Rushmeen Tariq, Olaf Klingbeil et al. · 2022 · Developmental Cell
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
Eva Pros, Maria Saigí, Daniel Alameda, Gema Gómez‐Mariano, Beatriz Martínez–Delgado, Juan J. Alburquerque-Béjar, Julián Carretero, Raúl Tonda, Anna Esteve‐Codina, I. Català et al. · 2020 · Annals of Oncology
Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET
Arpita S. Pal, Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates, Andrea L. Kasinski · 2022 · Cancer Research
Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer
Anna Solta, Büsra Ernhofer, Kristiina Boettiger, Zsolt Megyesfalvi, Simon Heeke, Mir Alireza Hoda, Christian Lang, Clemens Aigner, Fred R. Hirsch, Karin Schelch et al. · 2024 · Molecular Cancer
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
Zheng-Hai Tang, Xiaoming Jiang, Xia Guo, Chi Man Vivienne Fong, Xiuping Chen, Jin‐Jian Lu · 2016 · Oncotarget
Genomic signatures of pancreatic adenosquamous carcinoma (PASC)
Yuan Fang, Zhe Su, Jing Xie, Ruidong Xue, Qi Ma, Yanmeng Li, Yifan Zhao, Zeshi Song, Xiongxiong Lu, Hongwei Li et al. · 2017 · The Journal of Pathology
Lineage Plasticity: The New Cancer Hallmark on the Block
Arnav Mehta, Ben Z. Stanger · 2023 · Cancer Research
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1
Kathia E. Rodarte, Shaked Nir Heyman, Lei Ming Guo, Lydia Flores, Trisha K. Savage, Juan Villarreal, Su Deng, Lin Xu, Rajal B. Shah, Trudy G. Oliver et al. · 2024 · Cancer Research
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Xu Zhang, Tapan Kumar Maity, Manoj Kumar Kashyap, Mukesh Bansal, Abhilash Karavattu Venugopalan, Sahib Singh, Shivangi Awasthi, Arivusudar Marimuthu, Harrys K.C. Jacob, Natalya Belkina et al. · 2017 · Molecular & Cellular Proteomics
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy
Pierre Foidart, Cassandre Yip, Jean Radermacher, Silvia Blacher, Mehdi Liénard, Laetitia Montero‐Ruiz, Erik Maquoi, Élodie Montaudon, Sophie Château‐Joubert, Joëlle Collignon et al. · 2018 · Clinical Cancer Research
Modulating Cell Fate as a Therapeutic Strategy
Brian Lin, Priya Srikanth, Alison C. Castle, Sagar U. Nigwekar, Rajeev Kumar Malhotra, Jenna Lauren Galloway, David B. Sykes, Jayaraj Rajagopal · 2018 · Cell stem cell
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Alexandra N. Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa M. Coleman, Jared M. Lucas, Arja Kaipainen, Holly M. Nguyen, Daniel Sondheim, Lisha G. Brown, Lawrence D. True, John K. Lee et al. · 2019 · Clinical Cancer Research
FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice
Giustina Ferone, Ji‐Ying Song, Oscar Krijgsman, Jan van der Vliet, Miranda Cozijnsen, Ekaterina A. Semenova, David J. Adams, Daniel S. Peeper, Anton J. M. Berns · 2020 · Cell Reports
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
Nele Van Der Steen, Chiara Caparello, Christian Diego Rolfo, Patrick Pauwels, Godefridus J. Peters, Elisa Giovannetti · 2016 · OncoTargets and Therapy
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Sandra Cristea, Julien Sage · 2016 · Journal of Thoracic Oncology
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Àlvaro Quintanal-Villalonga, Vidushi Durani, Amin H. Sabet, Esther Redín, Kenta Kawasaki, Moniquetta Shafer, Wouter R. Karthaus, Samir Zaidi, Yingqian Ada Zhan, Parvathy Manoj et al. · 2023 · Science Translational Medicine
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
Alexandra Vander Ark, Jingchen Cao, Xiaohong Li · 2018 · Frontiers in Oncology
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows
Nuopei Tan, Yan Li, Jianming Ying, Wanqing Chen · 2024 · Journal of Translational Internal Medicine
Epithelial‐to‐mesenchymal transition and its role in EGFR‐mutant lung adenocarcinoma and idiopathic pulmonary fibrosis
Yuji Sakuma · 2017 · Pathology International
Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Jing Xu, Jinghui Wang, Shucai Zhang · 2017 · Oncotarget
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
Takeshi Jimbo, Mana Hatanaka, Takahiro Komatsu, Tomoe Taira, Kentaro Kumazawa, Naoyuki Maeda, Takashi Suzuki, Masahiro Ota, Noriyasu Haginoya, Takeshi Isoyama et al. · 2019 · Oncotarget
MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response
Huan Qiu, Bangming Jin, Zhanfeng Wang, Bin Xu, Qi‐Fan Zheng, Li Zhang, Ling-Yu Zhu, Shuang Shi, Jun-Bo Yuan, Xiao Lin et al. · 2020 · Nature Communications
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Emma Karlsen, Sam L. Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson · 2021 · Cells
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Manan P. Shah, Joel W. Neal · 2022 · Drugs
Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
Bin-Chi Liao, Chia‐Chi Lin, Jih‐Hsiang Lee, James Chih‐Hsin Yang · 2017 · Lung Cancer
Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammation
Shunsuke Kitajima, Chiaki Takahashi · 2017 · Cancer Science
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Daniel Botelho Costa, Susumu S. Kobayashi · 2015 · PubMed Central
Molecular alterations of neuroendocrine tumours of the lung
Giulio Rossi, Luca Bertero, Caterina Marchiò, Mauro Giulio Papotti · 2017 · Histopathology
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib
Jun Zhao, Gen Lin, Minglei Zhuo, Zaiwen Fan, Liyun Miao, Likun Chen, Aiping Zeng, Rong H. Yin, Yangming Ou, Zhihui Shi et al. · 2019 · Lung Cancer
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival
Chanyuan Zhang, Hao Sun, Junwei Su, Yuqing Chen, Shiling Zhang, Ming-Ying Zheng, Yufa Li, Jie Huang, Chao Zhang, Zaixian Tai et al. · 2022 · Lung Cancer
CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Aik Choon Tan, Hiroshi Mizuuchi, Leslie M. Rozeboom, Kim E. Ellison, Christopher J. Rivard, Tetsuya Mitsudomi et al. · 2018 · Molecular Cancer Therapeutics
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
Silvia La Monica, Claudia Fumarola, Daniele Cretella, Mara A. Bonelli, Roberta Minari, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Francesco Volta, Maicol Mancini et al. · 2020 · Cancers
Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer
Anna Keogh, Stephen P. Finn, Teodora Radonic · 2022 · Cancers
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
Kota Ishioka, Hiroyuki Yasuda, Junko Hamamoto, Hideki Terai, Katsura Emoto, Tae Jung Kim, Shigemichi Hirose, Takashi Kamatani, Sachiyo Mimaki, Daisuke Arai et al. · 2021 · Cancer Research